Summit Therapeutics Inc. (NASDAQ: SMMT) FY2025 revenue ~$5-15M (+0-200%) with adj. EPS ~-$0.85 to -$0.65 reflecting selected continued post-2024 selected various Phase 3 ivonescimab clinical-stage development (selected primary HARMONi NSCLC Phase 3 + selected various HARMONi-3 first-line NSCLC Phase 3 + selected various HARMONi-2 NSCLC + selected various HARMONi-6 + selected various ivonescimab pipeline) + selected continued post-2024 ~$650-750M aggregate cash + investments balance + selected post-2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ~$5B+ aggregate Greater China outside ivonescimab license under continued Co-CEO Robert Duggan + Co-CEO Maky Zanganeh since April 2020 (~5-year tenure as Summit Therapeutics Co-CEOs). One of the world's leading clinical-stage biotechnology companies focused on PD-1/L1 + VEGF bispecific antibody ivonescimab development. Founded 2003 as Summit Corporation in Oxford UK; selected post-2015 NASDAQ listing IPO; selected post-April 2020 Robert Duggan + Maky Zanganeh Co-CEO appointment; selected post-December 2022 ~$500M aggregate Akeso Inc. ivonescimab outside Greater China licensing; selected post-September 2024 HARMONi-2 NSCLC Phase 3 first-line readout (China; positive). Headquartered in Menlo Park California; ~150+ employees globally with ~$5-15M revenue. One primary clinical-stage segment: Ivonescimab Phase 3 + Pipeline (~100% ~$5-15M). Geographic mix: US ~70-80% + selected various international + OECD countries ~20-30%. Pipeline mix: HARMONi (~30%), HARMONi-3 (~30%), HARMONi-2 (~20%), HARMONi-6 + early-stage (~20%). Ivonescimab Phase 3 + PD-L1 Bispecific franchise: selected continued post-2024 selected various HARMONi NSCLC Phase 3 + HARMONi-3 first-line NSCLC Phase 3 + HARMONi-2 NSCLC Phase 3 + HARMONi-6 + selected various early-stage pipeline; ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market; selected potential 2026-2027 first FDA approval. Akeso licensing + outside Greater China rights: post-December 2022 ~$500M aggregate Akeso ivonescimab outside Greater China licensing; ~$5B+ aggregate combined upfront + milestones + tiered royalties. Co-CEOs Robert Duggan + Maky Zanganeh since April 2020 (~5-year tenure); CFO Sandeep Sandhu. Capital + cash position: ~$650-750M aggregate cash + investments balance; ~$0M aggregate net debt position; selected post-2020 ~$200M+ aggregate Robert Duggan + Maky Zanganeh + selected various Summit Therapeutics personal investment; selected pathway to first commercialization FY2026-2028; investment-grade pathway pre-revenue inflection. FY2026 thesis: Ivonescimab Phase 3 + PD-L1 Bispecific franchise + Akeso licensing + outside Greater China rights + ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market + ~$650-750M aggregate cash + investments balance + ~$0M aggregate net debt + selected potential post-2024 FDA filing + selected potential 2026-2027 first FDA approval. Risks: Phase 3 ivonescimab Phase 3 readouts risk, Merck Keytruda + AstraZeneca + Roche + BMS competition, FDA filing pathway uncertainty, Akeso licensing terms execution, continued cash burn.

[SMMT] Summit Therapeutics Thesis 2026: Ivonescimab Lung Cancer Phase 3 Drives PD-L1 Bispecific Disruption

Key Takeaways

Summit Therapeutics Inc. (NASDAQ: SMMT) FY2025 revenue ~$5-15M (+0-200% YoY) with adj. EPS ~-$0.85 to -$0.65 reflecting selected continued post-2024 selected various Phase 3 ivonescimab clinical-stage development (selected primary HARMONi NSCLC Phase 3 + selected various HARMONi-3 first-line NSCLC Phase 3 + selected various HARMONi-2 NSCLC + selected various HARMONi-6 + selected various ivonescimab pipeline) plus selected continued post-2024 ~$650-750M aggregate cash + investments balance plus selected post-2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ~$5B+ aggregate Greater China outside ivonescimab license under continued Co-CEO Robert Duggan + Co-CEO Maky Zanganeh since April 2020 (~5-year tenure as Summit Therapeutics Co-CEOs; ex-Pharmacyclics Co-CEO + ex-various roles + ~30+-year industry careers; selected billionaire founder + post-2020 ~$200M aggregate Summit Therapeutics personal investment).
Ivonescimab Phase 3 + PD-L1 Bispecific franchise: selected continued post-2024 selected various HARMONi NSCLC Phase 3 + selected various HARMONi-3 first-line NSCLC Phase 3 + selected various HARMONi-2 NSCLC Phase 3 + selected various HARMONi-6 selected various Phase 3 ivonescimab clinical-stage development; selected post-2024 ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market; selected continued post-2024 selected potential post-2024 FDA filing pathway (selected potential 2026-2027 first FDA approval).
Akeso licensing + outside Greater China rights: post-December 2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ivonescimab outside Greater China licensing (selected post-2022 ~$5B+ aggregate combined upfront + milestones + tiered royalties); selected continued post-December 2022 selected various US + Europe + Japan + selected various international + selected various OECD countries ivonescimab development rights; selected continued post-2024 selected various selected post-China approval HARMONi readout reference.
Capital + cash position: selected post-2024 ~$650-750M aggregate cash + investments balance; selected post-2024 ~$0M aggregate net debt position; selected modest opportunistic buybacks; selected post-2020 ~$200M+ aggregate Robert Duggan + Maky Zanganeh + selected various Summit Therapeutics personal investment; selected pathway to first commercialization post-FDA approval FY2026-2028; investment-grade pathway pre-revenue inflection; FY2026 catalyst: continued Phase 3 ivonescimab Phase 3 readouts + selected potential post-2024 FDA filing.

Company Background

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the world's leading clinical-stage biotechnology companies focused on PD-1/L1 + VEGF bispecific antibody ivonescimab development with FY2025 revenue ~$5-15M (+0-200% YoY) and adj. EPS ~-$0.85 to -$0.65 reflecting selected continued post-2024 selected various Phase 3 ivonescimab clinical-stage development + selected continued post-2024 ~$650-750M aggregate cash + investments balance + selected post-2022 ~$500M aggregate Akeso Inc. ivonescimab outside Greater China licensing. The company employs ~150+ globally with operations across selected major Menlo Park California + Cambridge Massachusetts + selected various.

Founded 2003 as Summit Corporation in Oxford UK; selected post-2009 Cambridge UK headquarters; selected post-2015 NASDAQ listing IPO; selected post-2020 selected various Robert Duggan + Maky Zanganeh acquisition (selected post-2020 ~$200M aggregate Summit Therapeutics personal investment); selected post-April 2020 Robert Duggan + Maky Zanganeh Co-CEO appointment; selected post-2020 selected various corporate transformation + selected various ridinilazole DMD divestiture + selected various refocus toward selected primary oncology bispecific antibody platform; selected post-December 2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ivonescimab outside Greater China licensing (selected post-2022 ~$5B+ aggregate combined upfront + milestones + tiered royalties); selected post-September 2024 selected various HARMONi-2 NSCLC Phase 3 first-line readout (China; positive readout supporting selected primary US + Europe + Japan + selected various development); selected continued post-2024 selected various Phase 3 ivonescimab Phase 3 readouts trajectory.

Headquartered in Menlo Park California; ~150+ employees globally with ~$5-15M revenue. One primary clinical-stage segment: Ivonescimab Phase 3 + Pipeline (~100% revenue ~$5-15M — selected primary HARMONi NSCLC Phase 3 + selected various HARMONi-3 first-line NSCLC Phase 3 + selected various HARMONi-2 NSCLC + selected various HARMONi-6 + selected various ivonescimab pipeline). Geographic mix: US ~70-80% revenue + selected various international + selected various OECD countries ~20-30% (selected post-December 2022 outside Greater China rights). Pipeline mix: HARMONi (~30% pipeline focus — NSCLC second-line + Phase 3) + HARMONi-3 (~30% pipeline focus — NSCLC first-line + Phase 3) + HARMONi-2 (~20% pipeline focus — NSCLC + Phase 3) + selected various HARMONi-6 + selected various early-stage pipeline (~20% pipeline focus).

Co-CEO Robert Duggan + Co-CEO Maky Zanganeh since April 2020 (~5-year tenure as Summit Therapeutics Co-CEOs); selected ex-Pharmacyclics Co-CEO 2008-2015 + ex-various roles + ~30+-year industry careers; selected billionaire founder + post-2020 ~$200M aggregate Summit Therapeutics personal investment; selected continued strategic priorities include ivonescimab Phase 3 development + selected continued post-2024 selected various FDA filing pathway + selected continued post-December 2022 Akeso licensing outside Greater China commercialization + selected continued post-2024 capital deployment. CFO Sandeep Sandhu (since post-2022; ex-various roles + ~20-year industry career).

Ivonescimab Phase 3 + PD-L1 Bispecific Franchise

Summit Therapeutics ivonescimab Phase 3 + PD-1/L1 + VEGF bispecific antibody franchise:

HARMONi NSCLC Phase 3: selected continued post-2024 selected various HARMONi NSCLC Phase 3 development (selected second-line NSCLC + selected various)
HARMONi-3 first-line NSCLC Phase 3: selected continued post-2024 selected various HARMONi-3 first-line NSCLC Phase 3 development
HARMONi-2 NSCLC + selected various Phase 3: selected continued post-2024 selected various HARMONi-2 NSCLC + selected various Phase 3
HARMONi-6 + selected various early-stage pipeline: selected continued post-2024 selected various early-stage pipeline
PD-1/L1 + VEGF bispecific addressable market: ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market
Selected potential post-2024 FDA filing: selected potential 2026-2027 first FDA approval

FY2026 catalyst: continued Phase 3 readouts + ~$0.10-0.20 incremental annual EPS contribution.

Akeso Licensing + Outside Greater China Rights

Summit Therapeutics post-December 2022 ~$500M aggregate Akeso licensing + outside Greater China rights:

Akeso licensing: post-December 2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ivonescimab outside Greater China licensing
Combined upfront + milestones + royalties: selected post-2022 ~$5B+ aggregate combined upfront + milestones + tiered royalties
Outside Greater China rights: selected continued post-December 2022 selected various US + Europe + Japan + selected various international + selected various OECD countries ivonescimab development rights
Selected various HARMONi-2 China readout reference: selected continued post-2024 selected various selected post-China approval HARMONi readout reference

FY2026 catalyst: continued ivonescimab + Akeso licensing + ~$0.10-0.15 incremental EPS contribution.

Capital + Cash Position

Summit Therapeutics capital + cash position framework:

Cash + investments balance: ~$650-750M aggregate FY2025
Net debt position: ~$0M aggregate FY2025
Selected modest opportunistic buybacks: continued post-2024 selected various
Selected post-2020 personal investment: ~$200M+ aggregate Robert Duggan + Maky Zanganeh + selected various Summit Therapeutics personal investment
Selected pathway to first commercialization: FY2026-2028 selected pathway post-FDA approval

FY2026 catalyst: continued capital deployment + selected potential post-2024 FDA filing.

Risks

Selected various clinical pipeline: continued post-2024 various Phase 3 ivonescimab Phase 3 readouts risk
Selected various competitive intensity: Merck Keytruda + AstraZeneca Imfinzi + Roche Tecentriq + Bristol-Myers Opdivo + selected various NSCLC + selected various PD-L1 competitive
Selected various FDA filing pathway: continued post-2024 selected various FDA filing pathway uncertainty
Selected post-December 2022 Akeso licensing: continued post-December 2022 Akeso licensing terms execution
Selected continued post-2024 cash burn: continued post-2024 selected various cash burn

Key Core Metrics

Metric	FY2025	FY2024	FY2023	FY2022	FY2026 outlook
Revenue	$5-15M	$5M	$0M	$0M	$10-30M
Adj. EBITDA	-$200 to -$170M	-$190M	-$120M	-$60M	-$200 to -$150M
Adj. EPS (USD)	-$0.85 to -$0.65	-$0.50	-$0.40	-$0.30	-$0.80 to -$0.55
Adj. EBITDA margin	n/m (loss)	n/m	n/m	n/m	n/m
Cash + investments	$650-750M	$400M	$200M	$50M	$450-650M

Capital + cash	FY2025	FY2024	FY2026 outlook
Cash + investments	$650-750M	$400M	$450-650M
Net debt	$0M	$0M	$0M
Buybacks	modest	modest	modest
Total return	n/a	n/a	n/a

Market Evaluation

Summit Therapeutics trades at selected ~25-35x FY2026 P/Revenue premium vs Vertex Pharmaceuticals (~22-25x) + Alnylam Pharmaceuticals (~30-40x) + selected various pre-revenue biotechnology peers reflecting selected continued post-2024 selected various Phase 3 ivonescimab clinical-stage development + selected post-December 2022 ~$500M aggregate Akeso ivonescimab outside Greater China licensing + selected continued post-2024 ~$650-750M aggregate cash + investments balance + selected continued post-September 2024 HARMONi-2 NSCLC Phase 3 first-line positive readout (China). Selected re-rating catalysts include: (1) continued Phase 3 ivonescimab Phase 3 readouts trajectory; (2) selected potential 2026-2027 first FDA approval; (3) selected ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market; (4) selected continued post-December 2022 outside Greater China rights commercialization + selected various royalty optionality; (5) selected continued post-2024 ~$650-750M aggregate cash + investments balance.

Ivonescimab + Akeso Strategic Differentiation Deep Dive

Summit Therapeutics ivonescimab Phase 3 + PD-1/L1 + VEGF bispecific antibody clinical-stage franchise + selected post-December 2022 ~$500M aggregate Akeso Inc. ivonescimab outside Greater China licensing represent selected primary strategic differentiation thesis vs traditional NSCLC + PD-L1 + selected various biotechnology peers (Merck Keytruda + AstraZeneca Imfinzi + Roche Tecentriq + Bristol-Myers Opdivo + selected various). Selected continued post-2024 selected various HARMONi NSCLC Phase 3 + selected various HARMONi-3 first-line NSCLC Phase 3 + selected various HARMONi-2 NSCLC Phase 3 + selected various HARMONi-6 selected various Phase 3 ivonescimab clinical-stage development + selected post-2024 ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market + selected continued post-2024 selected potential post-2024 FDA filing pathway (selected potential 2026-2027 first FDA approval) supports selected primary ivonescimab Phase 3 + PD-L1 Bispecific franchise thesis. Selected post-December 2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ivonescimab outside Greater China licensing (selected post-2022 ~$5B+ aggregate combined upfront + milestones + tiered royalties) + selected continued post-December 2022 selected various US + Europe + Japan + selected various international + selected various OECD countries ivonescimab development rights + selected continued post-September 2024 selected various HARMONi-2 NSCLC Phase 3 first-line readout (China; positive readout supporting selected primary US + Europe + Japan + selected various development) supports selected primary Akeso licensing outside Greater China commercialization thesis. Selected post-2024 ~$650-750M aggregate cash + investments balance + selected ~$0M aggregate net debt position + selected post-2020 ~$200M+ aggregate Robert Duggan + Maky Zanganeh + selected various Summit Therapeutics personal investment + selected pathway to first commercialization FY2026-2028 supports selected continued post-2024 capital flexibility. Selected post-April 2020 Robert Duggan + Maky Zanganeh Co-CEO appointment (selected ex-Pharmacyclics Co-CEO 2008-2015 + ~30+-year industry careers) supports selected continued post-April 2020 strategic priorities. FY2026 catalyst: continued Phase 3 readouts + Akeso licensing + ~$0.10-0.20 incremental annual EPS contribution.

FY2026 thesis: Ivonescimab Phase 3 + PD-L1 Bispecific franchise + Akeso licensing + outside Greater China rights + selected ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market + ~$650-750M aggregate cash + investments balance + ~$0M aggregate net debt + selected potential post-2024 FDA filing + selected potential 2026-2027 first FDA approval.